Blood glucose is usually measured using invasive methods involving pricking small needles into the skin. But people suffering from diabetes have to test their glucose levels many times a day. This repeated use of needles is inconvenient and can increase the risk of potential infections.
Medtronic (NYSE:MDT) today announced real-world data supporting the use of its smart insulin pen and CGM sensor combination.
A research team has successfully developed an innovative platform for diabetes treatment using bioink derived from pancreatic tissue and 3D bioprinting technology. This study was recently published online in Nature Communications. The team was led by Professor Jinah Jang at Pohang University of Science and Technology (POSTECH), along with Myungji Kim, a Ph.D. candidate.
Tandem Diabetes Care (Nasdaq:TNDM) announced today that it launched its next-generation Control-IQ+ automated insulin delivery algorithm in the U.S.
Vivani Medical (Nasdaq:VANI) announced today that it successfully administered the first GLP-1 implant in its LIBERATE-1 clinical trial.
Millions of people with type 2 diabetes could receive better treatment thanks to a new, simple low-cost tool, according to research announced at the Diabetes UK Professional Conference 2025 and published in The Lancet.
Medtronic (NYSE: MDT)+
announced today that the FDA approved its BrainSense adaptive deep brain stimulation (aDBS) platform.
Adding engineered human blood vessel-forming cells to islet transplants boosted the survival of the insulin-producing cells and reversed diabetes in a preclinical study led by Weill Cornell Medicine investigators. The new approach, which requires further development and testing, could someday enable the much wider use of islet transplants to cure diabetes.
JAMA today published outcomes from a study evaluating the safety and efficacy of the Insulet Omnipod 5 in adults with type 2 diabetes.
An enzyme called cyclin-dependent kinase 2 (CDK2) regulates the cell cycle and may have the potential to drive therapeutic resistance to common breast cancer drugs—including a class of targeted treatments known as CDK4/6 inhibitors. A new study led by Agnieszka Witkiewicz, MD, and Erik Knudsen, Ph.D., of Roswell Park Comprehensive Cancer Center and colleagues highlights the therapeutic impact of CDK2 inhibitors and is published in the journal Nature Communications.